Ribavirin and interferon combination for recurrent post-transplant hepatitis C: Which benefit beyond 6 months?

Journal of Hepatology

Volumn 37, Issue 2, 2002, Pages 274-276

  Bizollon, Thierry ^a   Trepo, Christian ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CYTOKINE; INTERLEUKIN 4; REBETRON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; ANTIVIRUS AGENT; INTERFERON;

ANEMIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; EDITORIAL; ERADICATION THERAPY; GENOTYPE; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHESIS; IMMUNE DEFICIENCY; LEUKEMIA; LIVER BIOPSY; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; VIROLOGY; VIRUS REPLICATION; DRUG COMBINATION; NOTE; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMAN; INTERFERONS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN; HUMANS;

EID: 0036022888     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00200-3     Document Type: Editorial

References (22)

1. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis
2. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis group
3. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C
4. Hepatitis C virus recurrence after liver transplantation
5. Long term outcome of hepatitis C infection after liver transplantation
6. HCV-related fibrosis progression following liver transplantation: Increase in recent patients
7. High incidence of allograft cirrhosis in hepatitis C virus genotype infection following transplantation: Relationship with rejection episodes
8. The association between hepatitis C infection and survival after orthotopic liver transplantation
9. Retransplantation for recurrent hepatitis C
10. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients
11. Interferon alpha therapy for hepatitis C virus infection after liver transplantation
12. An open trial of IFN alpha recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
13. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation
14. Ribavirin therapy for hepatitis C infection following liver transplantation
15. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus twelve month course of interferon alpha 2b with ribavirin
16. Combination of interferon alpha 2b plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study
17. Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation
18. Mechanisms of hepatic toxicity. Pathogenic mechanisms involved in hepatitis C virus-induced liver diseases
19. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation
20. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production but inhibits Th2 cytokine response
21. Long-term histological improvement and clearance of intra-hepatic HCV RNA following sustained response to IFN-ribavirine combination in liver transplanted patients with HCV recurrence
22. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients